Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The company's shares surged about ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a type of ovarian cancer without the disease getting worse in a late-stage trial ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing's syndrome) and prostate cancer. The views and ...

Corcept’s ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel reduced disease progression risk by 30% in ovarian cancer. Relacorilant patients had a median overall survival of 16.0 months ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...

In other recent news, Corcept Therapeutics has reported positive results from its pivotal Phase 3 ROSELLA trial, which evaluated relacorilant in combination with nab-paclitaxel for patients with ...

Corcept Therapeutics (CORT.O), opens new tab said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial.